Abstract

ABSTRACT Artificial intelligence or machine learning (AI/ML) based systems can be used to help personalize prescribing decisions for individual patients. These AI/ML clinical decision support systems may provide either specific or more open-ended recommendations for the most appropriate medications to prescribe. These systems must fundamentally relate to the label of the medicines involved. The label of a medicine is an approved guide that indicates how to prescribe the drug in a safe and effective manner. The label for a medicine may evolve as new information on safety and effectiveness emerges, leading to the addition or removal of warnings, drug-drug interactions, or to permit new indications. Therefore, any AI/ML recommendation system would need to reference these label updates. However, the speed and consistency which these updates are made may influence the safety of prescribing decisions, since change control procedures and revalidation of algorithms may slow down any changes. This is especially important if changes need to be made quickly to protect patients. These considerations highlight the important role that pharmacoepidemiologists and drug safety professionals must play within this conversation. Furthermore, the guiding role that regulators have in regulating the development and use of these AI/ML clinical decision support systems is highlighted.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call